Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

BUY
$1.12 - $1.57 $2,849 - $3,994
2,544 New
2,544 $3,000
Q3 2022

Nov 04, 2022

BUY
$1.1 - $12.2 $92,233 - $1.02 Million
83,849 New
83,849 $98,000
Q2 2022

Aug 03, 2022

SELL
$0.67 - $3.19 $42,957 - $204,530
-64,116 Closed
0 $0
Q1 2022

May 02, 2022

SELL
$2.22 - $3.45 $53,870 - $83,717
-24,266 Reduced 27.46%
64,116 $191,000
Q4 2021

Feb 23, 2022

BUY
$2.36 - $3.57 $69,228 - $104,722
29,334 Added 49.68%
88,382 $234,000
Q3 2021

Oct 28, 2021

SELL
$3.5 - $4.5 $22,400 - $28,800
-6,400 Reduced 9.78%
59,048 $265,000
Q2 2021

Aug 12, 2021

SELL
$3.09 - $4.54 $90,249 - $132,599
-29,207 Reduced 30.86%
65,448 $284,000
Q1 2021

Apr 26, 2021

BUY
$3.35 - $4.93 $25,362 - $37,325
7,571 Added 8.69%
94,655 $323,000
Q4 2020

Feb 02, 2021

BUY
$2.35 - $3.74 $129,475 - $206,059
55,096 Added 172.24%
87,084 $304,000
Q3 2020

Oct 14, 2020

BUY
$1.78 - $4.13 $56,938 - $132,110
31,988 New
31,988 $76,000
Q2 2020

Jul 13, 2020

SELL
$1.41 - $2.05 $4,655 - $6,769
-3,302 Closed
0 $0
Q1 2020

Apr 29, 2020

SELL
$1.27 - $3.0 $76,757 - $181,317
-60,439 Reduced 94.82%
3,302 $5,000
Q4 2019

Feb 05, 2020

BUY
$1.6 - $2.43 $35,366 - $53,712
22,104 Added 53.09%
63,741 $136,000
Q3 2019

Oct 15, 2019

BUY
$1.63 - $2.62 $67,868 - $109,088
41,637 New
41,637 $77,000
Q1 2019

Apr 18, 2019

SELL
$2.0 - $2.65 $61,532 - $81,529
-30,766 Closed
0 $0
Q4 2018

Jan 16, 2019

BUY
$2.08 - $3.36 $43,226 - $69,827
20,782 Added 208.15%
30,766 $70,000
Q3 2018

Oct 23, 2018

BUY
$2.6 - $3.59 $25,958 - $35,842
9,984 New
9,984 $32,000
Q2 2018

Jul 30, 2018

SELL
$2.83 - $4.11 $50,999 - $74,066
-18,021 Closed
0 $0
Q1 2018

Apr 26, 2018

BUY
$3.54 - $4.54 $41,318 - $52,990
11,672 Added 183.84%
18,021 $63,000
Q4 2017

Jan 10, 2018

BUY
$3.23 - $4.3 $20,507 - $27,300
6,349
6,349 $24,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.